Rhythm Pharmaceuticals Receives Positive Recommendation from NICE for ▼IMCIVREE® (setmelanotide) for Treatment of Obesity and Hyperphagia in Patients with Bardet-Biedl Syndrome
People living with BBS may experience insatiable hunger, also known as hyperphagia, and severe obesity beginning early in life.
- People living with BBS may experience insatiable hunger, also known as hyperphagia, and severe obesity beginning early in life.
- “Hyperphagia – the feeling of extreme hunger that stays with patients all the time – leads to early-onset, life-long, severe obesity that affects many aspects of daily living.
- Until now there have been no licensed treatments for obesity and hyperphagia caused by BBS.”
The final NICE recommendation is aligned to the European Marketing Authorization (EMA) and U.K. - Rhythm is moving ahead with submission to the Scottish Medicines Consortium with a decision expected in 2025.